These trials completed more than 12 months ago and should have reported results.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Listed as ongoing, but also has a completion date and reported results 2006-000445-19 Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma (MPM) with or without hemithoracic radiotherapy. A randomized multicenter phase II trial 2018-08-13 bad-data
Ongoing 2007-001108-19 Master protocol for mantle cell lymphoma A multicenter stratified phase II trial testing Everolimus (RAD001) for the treatment of patients with newly diagnosed and relapsed or therapy resistant mant... not-yet-due
Listed as ongoing, but also has a completion date and reported results 2007-002047-24 Trial SAKK 56/07 Dasatinib first-line treatment in gastrointestinal stromal tumors. A multicenter phase II trial. 2018-05-16 bad-data
Completed, but no date 2007-003977-22 Protocol SAKK 77/06 and SASL 23 Continuous sunitinib treatment in patients with unresectable hepatocellular carcinoma A multicenter phase II trial bad-data
Completed, but no date 2008-006012-38 Neoadjuvant radiotherapy and capecitabine with or without panitumumab in patients with advanced, K-ras unmutated rectal cancer. A randomized multicenter phase II trial. bad-data
Exempt 2008-006312-38 Neoadjuvant radiotherapy combined with capecitabine and sorafenib in patients with advanced, K-ras mutated rectal cancer. A randomized multicenter phase I/II trial. not-yet-due
Listed as ongoing, but also has a completion date and reported results 2009-011884-35 Sorafenib alone or in combination with everolimus in patients with unresectable hepatocellular carcinoma. A randomized multicenter phase II trial. 2016-03-18 bad-data
Reported results 2009-016584-10 Multimodal therapy with and without cetuximab in patients with locally advanced esophageal carcinoma. An open-label phase III trial 2018-12-09 due-trials
Reported results 2010-019965-27 Fulvestrant with or without AZD6244, a mitogen-activated protein kinase kinase (MEK) 1/2 inhibitor, in advanced stage breast cancer progressing after aromatase inhibitor: a randomized placebo-controll... 2016-09-15 due-trials
Listed as ongoing, but also has a completion date and reported results 2010-021253-39 Rituximab plus lenalidomide or rituximab monotherapy for untreated patients with follicular lymphoma in need of therapy. A randomized, open-label, multicentre phase II trial Studio open label, di ... 2023-01-27 bad-data
Reported results Terminated 2011-002965-39 Orteronel maintenance therapy in patients with metastatic castration resistant prostate cancer and non-progressive disease after first-line docetaxel therapy: A multicenter randomized double-blind pla... 2016-07-20 due-trials
Ongoing 2011-005840-87 Carboplatin chemotherapy and involved node radiotherapy in stage IIA/B seminoma not-yet-due
Completed, report not yet due 2014-001189-87 Prevention of Symptomatic Skeletal Events with Denosumab Administered every 4 Weeks versus every 12 Weeks - A Non-Inferiority Phase III trial Verhinderung von symptomatischen Komplikationen am Skel... 2024-06-20 not-yet-due
Reported results 2014-003893-17 Combination of ibrutinib and bortezomib followed by ibrutinib maintenance to treat patients with relapsed and refractory mantle cell lymphoma; a multicenter Phase I/II trial Kombinationstherapie... 2021-03-30 due-trials
Reported results 2014-005330-58 A phase I/II open label clinical trial assessing safety and efficacy of intravesical instillation of VPM1002BC in patients with recurrent non-muscle invasive bladder cancer after standard BCG therapy 2023-03-07 due-trials
Completed, report not yet due 2015-001482-57 Adjuvant aspirin treatment in PIK3CA mutated colon cancer patients. A randomized, double-blinded, placebo-controlled, phase III trial Ergänzende Aspirin-Behandlung bei Dickdarmkrebs. Eine randomi... 2024-02-01 not-yet-due
Listed as ongoing, but also has a completion date and reported results 2015-001487-19 Protocol SAKK 35/14 Rituximab with or without Ibrutinib for untreated patients with advanced follicular lymphoma in need of therapy. A randomized, double-blinded, SAKK and NLG collaborative Phase II t... 2023-07-15 bad-data
Reported results 2016-003599-39 PROMET - Multicenter, Randomized Phase II Trial of Salvage Radiotherapy +/- Metformin for Patients with Prostate Cancer after Prostatectomy Etude de phase II, randomisée, multicentrique de radiothé... 2022-08-04 due-trials
Listed as ongoing, but also has a completion date 2016-003996-23 ODM-201 maintenance therapy in patients with metastatic castration resistant prostate cancer (mCRPC) previously treated with novel hormonal agents and non-progressive disease after subsequent treatmen... 2023-11-15 bad-data
Completed, but no date, and reported results 2017-001016-11 Lurbinectedin Monotherapy in Patients with Progressive Malignant Pleural Mesothelioma. A Multicenter, Single-arm Phase II Trial Lurbinectedin Monotherapy in Patients with Progressive Malignant Pleu... bad-data
Ongoing 2017-003565-10 Neoadjuvant and adjuvant durvalumab in combination with neoadjuvant chemotherapy in patients with operable urothelial cancer. A multicenter, single-arm phase II Trial. Neoadjuvante und adjuvante Ko... not-yet-due
Reported results 2018-003648-22 Ribociclib-endocrine combination therapy versus chemotherapy as 1st line treatment in patients with visceral metastatic breast cancer. A multicenter, randomized phase III trial. Ribociclib-endokri... 2021-04-15 due-trials
Other 2019-000514-11 Reduced intensity radio-chemotherapy for stage IIA/B seminoma. A multicenter, open label phase II trial with two cohorts Radio-Chemotherapie mit reduzierter Intensität bei Patienten mit einem Semin... not-yet-due
Other 2020-003876-42 Assessing a ctDNA and PET-oriented therapy in patients with DLBCL. A multicenter, open-label, phase II trial Assessing a ctDNA and PET-oriented therapy in patients with DLBCL. A multicenter, open-l... not-yet-due